<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370304</url>
  </required_header>
  <id_info>
    <org_study_id>20110526-09</org_study_id>
    <nct_id>NCT01370304</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation (rTMS) Compared or Associated With Venlafaxine for Depressive Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat participants with a diagnosis of depressive disorder to
      assess the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in
      the treatment of depressive disorders compared venlafaxine only (the optimal medication) and
      to rTMS only. fMRI will be performed to determine if treatment response is related to changes
      in fMRI, and use it to investigate the respondence to the treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is remission</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>It will be evaluated using the Hamilton Depression Rating Scale (HDRS-17 &lt; 8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fMRI</measure>
    <time_frame>0,6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Using the Clinical Global Impression scale(CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QIDS-C30</measure>
    <time_frame>1-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UKU Scale</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>Side effects will be assessed using the UKU Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>active rTMS and active Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>active rTMS and sham Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham rTMS and active Venlafaxine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active rTMS and active Venlafaxine</intervention_name>
    <description>rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks</description>
    <arm_group_label>active rTMS and active Venlafaxine</arm_group_label>
    <other_name>venlafaxine: Wyeth</other_name>
    <other_name>rTMS: MagVenture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active rTMS and sham Venlafaxine</intervention_name>
    <description>rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks</description>
    <arm_group_label>active rTMS and sham Venlafaxine</arm_group_label>
    <other_name>venlafaxine: Wyeth</other_name>
    <other_name>rTMS: MagVenture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham rTMS and active Venlafaxine</intervention_name>
    <description>rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks</description>
    <arm_group_label>sham rTMS and active Venlafaxine</arm_group_label>
    <other_name>venlafaxine: Wyeth</other_name>
    <other_name>rTMS: MagVenture</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Clinical diagnosis of major depressive disorder (DSM-IV)

          -  HDRS-17 items &gt; 20

          -  Failure of one antidepressant treatment (efficacious doses for 6 weeks at least)

        Exclusion Criteria:

          -  Psychotic features

          -  Failure of one previous venlafaxine treatment

          -  Addiction comorbidity or schizophrenia comorbidity

          -  Involuntary hospitalization

          -  Seizures history

          -  Pregnancy or breastfeeding

          -  Somatic comorbidity able to impact on cognitive functions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingrong Tan, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Psychiatry, Xi Jing hospital, Xi'an, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunchun Chen, Ph.D</last_name>
    <phone>+086-13720582601</phone>
    <email>Yunchunchen@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shufang Feng, Ph.D</last_name>
    <phone>+086-13227807801</phone>
    <email>fangshuan1984@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yun chun Chen</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun chun Chen, Ph.D</last_name>
      <phone>+086-13720582601</phone>
      <email>Yunchunchen@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shufang Feng, Ph.D</last_name>
      <phone>+086-13227807801</phone>
      <email>fangshuan1984@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhuo Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>fengshufang</investigator_full_name>
    <investigator_title>Fourth Military Medical University, Department of Psychosomatics, Xijing Hospital</investigator_title>
  </responsible_party>
  <keyword>repetitive Transcranial Magnetic Stimulation (rTMS)</keyword>
  <keyword>Depression</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

